Assay News and Research

RSS

In Southeast Asia, robust immunity found up to 9 months after SARS-CoV-2 infection

Now, a new study posted to the bioRxiv* preprint server focuses on functional immune memory to SARS-CoV-2, up to nine months in a Southeast Asian cohort, in the absence of re-infection.

16 Aug 2021

Moderna COVID-19 vaccine safe and efficacious in adolescents according to a new study

The safety, immunogenicity, and efficacy of the vaccines in adolescents are largely unknown. Now, a new study published in the New England Journal of Medicine evaluates the safety and efficacy of the mRNA-1273 vaccine in adolescents (12-17 years of age).

16 Aug 2021

Viral load could not predict transmissibility of SARS-CoV-2, study finds

The transmission of SARS-CoV-2 virus is dependent on many factors. Although some in vitro studies indicate that the amount of virus isolated from infected individuals affects the successful rate of virus transmission, whether the viral load carried at the individual level can determine transmissibility was unknown.

16 Aug 2021

Obtained SARS-CoV-2 immunity, naturally or via vaccination persists 12 months

In a research paper recently uploaded to the preprint server medRxiv* by Havervall et al. (August 12th, 2021), neutralizing antibody titers towards wild-type SARS-CoV-2 and several variants of concern in individuals having either been vaccinated or infected with mild COVID-19 one year earlier are assessed, finding a reduced neutralization capacity against some strains.

16 Aug 2021

Response to a third SARS-CoV-2 vaccine dose amongst immunocompromised

In a research paper recently uploaded to the preprint server medRxiv* by Schrezenmeier et al. (August 12th, 2021) the potential benefit of three vaccine doses in either a homogenous or heterogeneous dosing regimen amongst kidney transplant patients is assessed, finding that the search for viable vaccination approaches amongst these patients remains an urgent medical need.

16 Aug 2021

Primate study shows benefit of mRNA vaccine booster shot against SARS-CoV-2 variants

In a recent bioRxiv* preprint research paper, a large group of US scientists demonstrate how a booster dose of the mRNA-1273 vaccine can substantially improve both the potency and range of neutralizing antibody responses and mediate protection against upper and lower airway infection by a range of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern – even those relatively resistant to in vitro neutralization.

16 Aug 2021

Research suggests toll-like receptor 4 appears to play role in severe COVID

A group of researchers re-evaluated their previously proposed hypothesis, which stated that the TLR4 activated by the spike glycoprotein S1 domain increases ACE2 expression and, thereby, aids in COVID-19 infection.

16 Aug 2021

Direct evidence in hamsters shows SARS-CoV-2 is airborne

Evidence suggests that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can be transmitted without contact by respiratory droplets and aerosols bearing the virus when coughing, sneezing, speaking, and breathing. The virus has been cultured from aerosols collected nearby COVID-19 patients, and such aerosols can linger in still air for hours.

15 Aug 2021

SARS-CoV-2 detection by machine learning surface-enhanced Raman spectroscopy

Surface-enhanced Raman spectroscopy is a highly sensitive molecule characterization method, significantly more sensitive than ordinary Raman spectroscopy due to the excitation of Raman modes matching the plasmon resonance frequency of the surface metal utilized, usually gold, silver, or copper.

11 Aug 2021

Immunogenicity of mRNA vaccine against emerging strains of SARS-CoV-2 in immunocompromised patients

A study measured neutralization of SARS-CoV-2 and vaccine responses in immunocompromised patients with systemic inflammatory diseases.

11 Aug 2021

Evaluation of mRNA vaccine responses with a surrogate SARS-CoV-2 viral neutralization assay

In the current study, the authors evaluate several different competitive ELISAs that could be used to measure serum antibodies.

11 Aug 2021

Plant-based virus-like particle vaccine induces durable immune response against SARS-CoV-2 variants

Scientists from Germany and Belgium have recently described the immunogenicity of a plant-based virus-like particle vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The vaccine induces robust antibody and T cell responses for at least 6 months. Moreover, the vaccine demonstrates potent neutralizing efficacy against the B.1.1.7, B.1.351, and P1 variants of SARS-CoV-2.

11 Aug 2021

Cardioprotective role of HIF1α in COVID-19 patients

The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which first emerged in Wuhan, China, in late December 2019, has quickly become the most urgent issue facing scientists worldwide. It has been reported that the respiratory infection causes cardiac dysfunction in 25-55% patients, including hospitalized patients and non-critical patients.

10 Aug 2021

Controlling the spread of SARS-CoV-2 at a large public university

Researchers from the U.S. recently reported a multimodal "SHIELD: Target, Test, and Tell" program that helped mitigate the transmission of SARS-CoV-2 at a large public university. The program also prevented community transmission and helped the continuation of in-person classes during the pandemic. This study is available on the medRxiv* preprint server.

9 Aug 2021

Quanterix Simoa® Technology Powers Breakthrough Alzheimer’s Disease Research Presented by Eli Lilly and Company at Alzheimer’s Association International Conference (AAIC) 2021

Ultra-sensitive Simoa® HD-X technology powers new findings that detect rapid reduction of plasma P-tau217 from donanemab, Lilly’s investigational antibody therapy for Alzheimer's disease at 12 weeks

From Quanterix 9 Aug 2021

Study of antibody responses to COVID-19 mRNA vaccine in convalescent individuals

In addition to clinical trials conducted to determine the safety and efficacy of the mRNA vaccines, additional studies began describing the serological response to the vaccines under "real-world" conditions, especially with the onset of the SARS-CoV-2 variants and case reports of vaccine escape.

9 Aug 2021

Research shows how SARS-CoV-2 variants are evolving towards increased furin cleavage efficiency

The spike protein comprises of two subunits: S1 subunit having the receptor-binding domain (RBD) that helps it to bind to the angiotensin-converting enzyme 2 (ACE2), which is present on the cell surface of the host, and the S2 subunit that helps in the fusion of the cellular membrane and the viral membrane.

9 Aug 2021

Scientists identify calpeptin as potential inhibitor of SARS-CoV-2

A team of US-based scientists has recently conducted a robust high-throughput screening to identify potential entry inhibitors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The screening identifies calpeptin as a potent and highly specific inhibitor of SARS-CoV-2 and its variants. The study is currently available on the bioRxiv* preprint server.

9 Aug 2021

Cetylpyridinium chloride-containing mouthwashes shown to inhibit SARS-CoV-2 in oral cavity

A team of international scientists has recently demonstrated the usefulness of cetylpyridinium chloride-containing mouthwashes in inhibiting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and reducing the risk of viral transmission. The study is currently available on the bioRxiv* preprint server.

9 Aug 2021

New insight into impact of SARS-CoV-2 mutations on receptor binding

A recent study by Canadian researchers, currently available on the bioRxiv* preprint server, contributes to the growing body of literature on emerging variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by appraising the impact of single mutations on their overall antigenicity and binding affinity for the angiotensin-converting enzyme 2 (ACE2) receptor.

9 Aug 2021

Assay News and Research

In Southeast Asia, robust immunity found up to 9 months after SARS-CoV-2 infection

Moderna COVID-19 vaccine safe and efficacious in adolescents according to a new study

Viral load could not predict transmissibility of SARS-CoV-2, study finds

Obtained SARS-CoV-2 immunity, naturally or via vaccination persists 12 months

Response to a third SARS-CoV-2 vaccine dose amongst immunocompromised

Primate study shows benefit of mRNA vaccine booster shot against SARS-CoV-2 variants

Research suggests toll-like receptor 4 appears to play role in severe COVID

Direct evidence in hamsters shows SARS-CoV-2 is airborne

SARS-CoV-2 detection by machine learning surface-enhanced Raman spectroscopy

Immunogenicity of mRNA vaccine against emerging strains of SARS-CoV-2 in immunocompromised patients

Evaluation of mRNA vaccine responses with a surrogate SARS-CoV-2 viral neutralization assay

Plant-based virus-like particle vaccine induces durable immune response against SARS-CoV-2 variants

Cardioprotective role of HIF1α in COVID-19 patients

Controlling the spread of SARS-CoV-2 at a large public university

Quanterix Simoa® Technology Powers Breakthrough Alzheimer’s Disease Research Presented by Eli Lilly and Company at Alzheimer’s Association International Conference (AAIC) 2021

Study of antibody responses to COVID-19 mRNA vaccine in convalescent individuals

Research shows how SARS-CoV-2 variants are evolving towards increased furin cleavage efficiency

Scientists identify calpeptin as potential inhibitor of SARS-CoV-2

Cetylpyridinium chloride-containing mouthwashes shown to inhibit SARS-CoV-2 in oral cavity

New insight into impact of SARS-CoV-2 mutations on receptor binding

eBook: Using iPSCs models for human disease research and drug discovery eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News